Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 8
2003 8
2004 5
2005 12
2006 9
2007 10
2008 5
2009 14
2010 13
2011 10
2012 13
2013 17
2014 12
2015 10
2016 19
2017 21
2018 14
2019 11
2020 15
Text availability
Article attribute
Article type
Publication date

Search Results

194 results
Results by year
Filters applied: . Clear all
Page 1
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.
Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli A. Germano G, et al. Among authors: d incalci m. Nature. 2017 Dec 7;552(7683):116-120. doi: 10.1038/nature24673. Epub 2017 Nov 29. Nature. 2017. PMID: 29186113 Free article.
Role of macrophage targeting in the antitumor activity of trabectedin.
Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P. Germano G, et al. Among authors: d incalci m. Cancer Cell. 2013 Feb 11;23(2):249-62. doi: 10.1016/j.ccr.2013.01.008. Cancer Cell. 2013. PMID: 23410977 Free article.
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Grignani G, D'Ambrosio L, Pignochino Y, Palmerini E, Zucchetti M, Boccone P, Aliberti S, Stacchiotti S, Bertulli R, Piana R, Miano S, Tolomeo F, Chiabotto G, Sangiolo D, Pisacane A, Dei Tos AP, Novara L, Bartolini A, Marchesi E, D'Incalci M, Bardelli A, Picci P, Ferrari S, Aglietta M. Grignani G, et al. Among authors: d incalci m. Lancet Oncol. 2018 Oct;19(10):1360-1371. doi: 10.1016/S1470-2045(18)30438-8. Epub 2018 Sep 11. Lancet Oncol. 2018. PMID: 30217671 Clinical Trial.
High-dose vitamin C enhances cancer immunotherapy.
Magrì A, Germano G, Lorenzato A, Lamba S, Chilà R, Montone M, Amodio V, Ceruti T, Sassi F, Arena S, Abrignani S, D'Incalci M, Zucchetti M, Di Nicolantonio F, Bardelli A. Magrì A, et al. Among authors: d incalci m. Sci Transl Med. 2020 Feb 26;12(532):eaay8707. doi: 10.1126/scitranslmed.aay8707. Sci Transl Med. 2020. PMID: 32102933 Free article.
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
Belgiovine C, Bello E, Liguori M, Craparotta I, Mannarino L, Paracchini L, Beltrame L, Marchini S, Galmarini CM, Mantovani A, Frapolli R, Allavena P, D'Incalci M. Belgiovine C, et al. Among authors: d incalci m. Br J Cancer. 2017 Aug 22;117(5):628-638. doi: 10.1038/bjc.2017.205. Epub 2017 Jul 6. Br J Cancer. 2017. PMID: 28683469 Free PMC article.
HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance.
Loria R, Laquintana V, Bon G, Trisciuoglio D, Frapolli R, Covello R, Amoreo CA, Ferraresi V, Zoccali C, Novello M, Del Bufalo D, Milella M, Biagini R, D'Incalci M, Falcioni R. Loria R, et al. Among authors: d incalci m. Oncogene. 2018 Nov;37(45):5926-5938. doi: 10.1038/s41388-018-0394-x. Epub 2018 Jul 6. Oncogene. 2018. PMID: 29980789 Free PMC article.
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
Colombo N, Zaccarelli E, Baldoni A, Frezzini S, Scambia G, Palluzzi E, Tognon G, Lissoni AA, Rubino D, Ferrero A, Farina G, Negri E, Pesenti Gritti A, Galli F, Biagioli E, Rulli E, Poli D, Gerardi C, Torri V, Fossati R, D'Incalci M. Colombo N, et al. Among authors: d incalci m. Br J Cancer. 2019 Oct;121(9):744-750. doi: 10.1038/s41416-019-0584-5. Epub 2019 Sep 20. Br J Cancer. 2019. PMID: 31537908 Free PMC article. Clinical Trial.
Professor Maurizio D'Incalci interviewed by Emma Cannell.
D'Incalci M. D'Incalci M. Eur J Cancer. 2002 Aug;38(12):1559. Eur J Cancer. 2002. PMID: 12216541 No abstract available.
Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.
Frapolli R, Bello E, Ponzo M, Craparotta I, Mannarino L, Ballabio S, Marchini S, Carrassa L, Ubezio P, Porcu L, Brich S, Sanfilippo R, Casali PG, Gronchi A, Pilotti S, D'Incalci M. Frapolli R, et al. Among authors: d incalci m. Clin Cancer Res. 2019 Dec 15;25(24):7565-7575. doi: 10.1158/1078-0432.CCR-19-0976. Epub 2019 Sep 3. Clin Cancer Res. 2019. PMID: 31481505
Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study.
Calura E, Ciciani M, Sambugaro A, Paracchini L, Benvenuto G, Milite S, Martini P, Beltrame L, Zane F, Fruscio R, Marchette MD, Borella F, Tognon G, Ravaggi A, Katsaros D, Bignotti E, Odicino F, D'Incalci M, Marchini S, Romualdi C. Calura E, et al. Among authors: d incalci m. Cells. 2019 Dec 1;8(12):1554. doi: 10.3390/cells8121554. Cells. 2019. PMID: 31805750 Free PMC article.
194 results
Jump to page
Feedback